Dr Reddys Laboratories Ltd - DR REDDYS LABS Share Price

Sector: Pharmaceuticals | ISIN: INE089A01023
₹ 5,587.00 (2.91%) icon29 Sep, 2023, 3:55:10 PM
Open
₹ 5,469.00
Prev. Close
₹ 5,429.10
Turnover(lac)
₹ 34,661.25
Day's High
₹ 5,630.00
Day's Low
₹ 5,453.25
52 Wk High
₹ 5,989.70
52 Wk Low
₹ 4,175.10
Book Value
₹ 1,333.49
Face Value
₹ 5.00
Mkt. Cap (Cr.)
₹ 93,182.65
P/E
24.83
EPS
225.00
Div. Yield
0.72

Dr Reddys Laboratories Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 9/29/2023 3:55:10 PM

    ₹ 5587 157.90 2.91
  • Open
  • ₹ 5,469
  • Prev. Close
  • ₹ 5,429.1
  • Turnover(Lac.)
  • ₹ 34,661
  • Day's High
  • ₹ 5,630
  • Day's Low
  • ₹ 5,453.25
  • 52 Week's High
  • ₹ 5,989.7
  • 52 Week's Low
  • ₹ 4,175.1
  • Book Value
  • ₹ 1,333.49
  • Face Value
  • ₹ 5
  • Mkt Cap (₹ Cr.)
  • 93,182.65
  • P/E
  • 24.83
  • EPS
  • 225
  • Divi. Yield
  • 0.72

Dr Reddys Laboratories Ltd Corporate Actions

10 May , 2023

12:00 AM

AGM

Announcement date: 10 May , 2023

View Details

21 Jun , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

21 Jun , 2023

12:00 AM

10 May , 2023

12:00 AM

Dividend

Dividend amount: 40
Announcement date: 10 May , 2023

View Details

23 Mar , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 Mar , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Dec , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Dec , 2022

12:00 AM

28 Sep , 2022

12:00 AM

28 Sep , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

10 May , 2023

12:00 AM

BookCloser

View Details

Dr Reddys Laboratories Ltd News and Update

Image not found
  • 29 September, 2023 |
  • 8:36 PM

According to a BSE notification dated September 28, it will be involved in the importing, warehousing, distribution, and exportation of pharmaceuticals.

Image not found
Article Image
  • IIFL News Service |
  • 29 September, 2023 |
  • 8:35 PM
Image not found
  • IIFL News Service |
  • 28 September, 2023 |
  • 8:34 PM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Dr Reddys Laboratories Ltd SHAREHOLDING SNAPSHOT
02 October , 2023 | 08:09 AM

PROMOTER - TOTAL26.69%

Indian: 26.69%

Foreign: 0%

NON-PROMOTER - TOTAL 73.10%

Institutions: 61.52%

Non-Institutions: 11.57%

CUSTODIES - 0.21%

Custodies: 0.21%

See More Details
ad IconAd Image

Dr Reddys Laboratories Ltd FINANCIALS

Dr Reddys Laboratories Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Dr Reddys Laboratories Ltd

  • G V Prasad
  • Co-Chairman & Managing Directo
  • K Satish Reddy
  • Executive Chairman
  • Kalpana Morparia
  • Independent Director
  • Shikha Sanjaya Sharma
  • Independent Director
  • Leo Puri
  • Independent Director
  • K P Krishnan
  • Independent Director
  • Pennv Wan
  • Independent Director
  • K Randhir Singh
  • Company Sec. & Compli. Officer
  • Arun M. Kumar
  • Independent Director
  • Claudio Albrecht
  • Independent Director

Summary

Dr Reddys Laboratories Ltd (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddys offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The companys major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddys operates in markets across the globe. Its major markets include - USA, India, Russia & CIS countries, and Europe.Dr Reddys Laboratories was incorporated in the year 1984 in Hyderabad. The company was established by Dr Anji Reddy with an initial capital outlay of Rs 25 lakh. The company made their beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (API) and commenced operations with a single drug in a 60-tonne facility near Hyderabad, India. In the year 1986, the company shares were listed on the Bombay Stock Exchange. Also, they entered international market with exports of Methyldopa.In the year 1987, the company obtained first USFDA approval for Ibuprofen API. In the year 1988, they acquired Benzex Laboratories Pvt Ltd to expand their Bulk Actives business. In the year 1990, they exported Norfloxacin and Ciprofloxacin to... Read More


Reports by Dr Reddys Laboratories Ltd


Reports by Dr Reddys Laboratories Ltd

Company FAQ

No Record Found